WASP-1, a canonical Wnt signaling potentiator, rescues hippocampal synaptic impairments induced by Aβ oligomers

Exp Neurol. 2015 Feb:264:14-25. doi: 10.1016/j.expneurol.2014.11.005. Epub 2014 Nov 20.

Abstract

Amyloid-β (Aβ) oligomers are a key factor in Alzheimer's disease (AD)-associated synaptic dysfunction. Aβ oligomers block the induction of hippocampal long-term potentiation (LTP) in rodents. The activation of Wnt signaling prevents Aβ oligomer-induced neurotoxic effects. The compound WASP-1 (Wnt-activating small molecule potentiator-1), has been described as a synergist of the ligand Wnt-3a, enhancing the activation of Wnt/β-catenin signaling. Herein, we report that WASP-1 administration successfully rescued Aβ-induced synaptic impairments both in vitro and in vivo. The activation of canonical Wnt/β-catenin signaling by WASP-1 increased synaptic transmission and rescued hippocampal LTP impairments induced by Aβ oligomers. Additionally, intra-hippocampal administration of WASP-1 to the double transgenic APPswe/PS1dE9 mouse model of AD prevented synaptic protein loss and reduced tau phosphorylation levels. Moreover, we found that WASP-1 blocked Aβ aggregation in vitro and reduced pathological tau phosphorylation in vivo. These results indicate that targeting canonical Wnt signaling with WASP-1 could have value for treating AD.

Keywords: Alzheimer's disease; Aβ oligomers; Synaptic plasticity; Synaptic proteins; WASP-1; Wnt signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / toxicity
  • Amyloid beta-Protein Precursor / genetics
  • Animals
  • CCN Intercellular Signaling Proteins / therapeutic use*
  • Cells, Cultured
  • Excitatory Postsynaptic Potentials / drug effects
  • Excitatory Postsynaptic Potentials / genetics
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / genetics
  • Hippocampus / drug effects*
  • Hippocampus / pathology
  • Hippocampus / physiology
  • Humans
  • Male
  • Mice
  • Mice, Transgenic
  • Neurons / drug effects*
  • Neurotoxicity Syndromes / drug therapy*
  • Neurotoxicity Syndromes / etiology
  • Neurotoxicity Syndromes / genetics
  • Neurotoxicity Syndromes / pathology*
  • Phosphorylation / drug effects
  • Phosphorylation / genetics
  • Presenilin-1 / genetics
  • Proto-Oncogene Proteins / therapeutic use*
  • Rats
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Synapses / drug effects*
  • Synapses / genetics
  • Synapses / physiology
  • Synapses / ultrastructure
  • Time Factors

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • CCN Intercellular Signaling Proteins
  • CCN4 protein, human
  • PSEN1 protein, human
  • Presenilin-1
  • Proto-Oncogene Proteins